Item 8.01 - Other Events.

Abbott Laboratories has reached settlements in the litigation pending in the United States District Court for the District of Delaware involving direct purchaser class action claims and claims brought by certain individual plaintiffs related to the sale of fenofibrate formulations. Under the settlements, Abbott will pay approximately $184 million to resolve these claims. Settlement agreements have also been reached resolving some of the other previously disclosed fenofibrate litigation. The amounts in those settlements are not material. Abbott intends to treat the settlement payments as a specified item in the fourth quarter 2008.

Private Securities Litigation Reform Act of 1995 - A Caution Concerning Forward-Looking Statements

Some statements in this Form 8-K may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to Abbott's Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2007, and in Item 1A, "Risk Factors," to Abbott's Quarterly Reports on Securities and Exchange Commission Form 10-Q for the quarters ended June 30, 2008, and September 30, 2008, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.